MedTrace Logo

A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 Diabetes

NCT00674986 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 522

Last updated 2013-10-21

Study results available
· View outcomes & findings →

Summary

This randomized, parallel group study will determine whether the use of episodic, intensive glucose monitoring via the Accu-Chek 360 view blood glucose analysis system has a positive effect on overall glycemic control. Patients will be randomized into either the 'usual care' group, or the 'interventional group' supplemented with the Accu-Chek 360 view blood glucose analysis system. The effect of each treatment regimen on glycemic control will be assessed by measurement of change in baseline HbA1c values at 12 months. The anticipated time on study treatment is 1 year, and the target sample size is 504 individuals.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DEVICE

Accu-Chek 360° View Blood Glucose Analysis Tool

DEVICE

Accu-Chek Aviva Glucose Meter

Sponsors & Collaborators

Principal Investigators

  • Bettina Petersen · Roche Diagnostics GmbH

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00674986 on ClinicalTrials.gov